Article Text

Download PDFPDF
MECP2 mutation in non-fatal, non-progressive encephalopathy in a male
  1. Belaïd Imessaoudene*,
  2. Jean-Paul Bonnefont,
  3. Ghislaine Royer,
  4. Valérie Cormier-Daire,
  5. Stanislas Lyonnet,
  6. Gilles Lyon,
  7. Arnold Munnich,
  8. Jeanne Amiel
  1. Département de Génétique and INSERM U-393, Hôpital Necker-Enfants Malades, 149 rue de Sèvres, 75743 Paris Cedex 15, France
  1. Dr Amiel, amiel{at}


To study the clinical overlap between Rett (RTT) and Angelman syndromes (AS), we screened the MECP2 gene in a cohort of 78 patients diagnosed as possible AS but who showed a normal methylation pattern at the UBE3Alocus. MECP2 missense (R106W, G428S), nonsense (R255X, R270X), and frameshift mutations (803 delG) were identified in 6/78 patients including 4/6 female cases consistent with RTT, one female case with progressive encephalopathy of neonatal onset, and one isolated male case with non-fatal, non-progressive encephalopathy of neonatal onset. This study shows thatMECP2 mutations can account for a broad spectrum of clinical presentations and raises the difficult issue of the screening of the MECP2 gene in severe encephalopathy in both males and females.

  • MECP2 gene
  • Rett syndrome
  • Angelman syndrome
  • encephalopathy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • * Present address: Laboratoire de Biochimie, Service du Pr Berhoune, CHU Alger Centre et Hôpital Mustapha, Alger, Algeria